Transaction Description
Gemstone Capital acted as financial advisor in Brain+’s rights issue. The company resolved to carry out a preferential rights issue of units of initially approximately DKK 15.7 million (the “Rights Issue”), in accordance with the previously published company announcement on 29 March 2023. The rights issue was subscribed to a total of approximately 88 percent, including presubscription and guarantee commitments. Brain+ was thus provided proceeds of approximately DKK 13.8 million before deduction of transaction related costs.
Contact Person
Company Description
Brain+ is a pioneer in developing medical software to treat the cognitive symptoms of dementia, and the most common cause of dementia, namely Alzheimer’s disease. Together with world-leading experts and institutions, the Company digitize the best-in-class, non-drug dementia therapies, and make them broadly available on standard digital devices – for use both in people’s homes and at healthcare clinics. This approach is referred to as Digital Therapeutics or Digital Medicine.
